Artwork

Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

New Drug Approved for Ultra-Orphan Niemann-Pick C Disease with Dr. Adrian Quartel Zevra Therapeutics

21:23
 
공유
 

Manage episode 455972430 series 99915
Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Dr. Adrian Quartel, Chief Medical Officer at Zevra Therapeutics, has received FDA approval for their drug MIPLYFFA in combination with miglustat, the first treatment in the US for Niemann-Pick type C, an ultra-orphan disease. This hard to diagnose, rare genetic lysosomal storage disorder affects the recycling of cholesterol and lipids in cells, leading to neurological and physical problems. The Amplify Assist program has been set up to help patients access and afford the treatment.

Adrian elaborates, "Niemann-Pick C is a very rare or ultra-orphan disease. It's one of what is considered a lysosomal storage disorder. I'll try to explain a little bit about what that means. So lysosomes are little organelles or little systems within the cell that are basically the waste disposal system from the cell. They break down worn-out parts on the inside of the cells, or they break down harmful molecules and waste products. They're effectively recycling materials in the cell. So, any lysosomal storage disorder actually affects the system where waste products are recycled within the cell. In Niemann-Pick C disease, it's specific for lipids such as cholesterol or sphingolipids inside the cell that need to be recycled."

"The early onset of the late infantile onset usually occurs before the age of 10. Then, you have the juvenile and adult-onset, which usually occurs after the age of 10 and have different types of symptoms. Once you have the neurological symptoms, they usually start with delay in motor milestones in the younger children. But most often, we see a diagnosis happening between the ages of, say, three and seven, starting with problems in walking, stability or gait problems, clumsiness, delay in speech, or losing the ability to speak appropriately, as well as seizures, problems at school, problems to follow direction at school, some behavioral problems."

#ZevraTherapeutics #RareDisease #OrphanDisease #NiemannPick #NPC #NiemannPickAwareness #PediatricRareDisease

zevra.com

Download the transcript here

  continue reading

2103 에피소드

Artwork
icon공유
 
Manage episode 455972430 series 99915
Karen Jagoda에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Karen Jagoda 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Dr. Adrian Quartel, Chief Medical Officer at Zevra Therapeutics, has received FDA approval for their drug MIPLYFFA in combination with miglustat, the first treatment in the US for Niemann-Pick type C, an ultra-orphan disease. This hard to diagnose, rare genetic lysosomal storage disorder affects the recycling of cholesterol and lipids in cells, leading to neurological and physical problems. The Amplify Assist program has been set up to help patients access and afford the treatment.

Adrian elaborates, "Niemann-Pick C is a very rare or ultra-orphan disease. It's one of what is considered a lysosomal storage disorder. I'll try to explain a little bit about what that means. So lysosomes are little organelles or little systems within the cell that are basically the waste disposal system from the cell. They break down worn-out parts on the inside of the cells, or they break down harmful molecules and waste products. They're effectively recycling materials in the cell. So, any lysosomal storage disorder actually affects the system where waste products are recycled within the cell. In Niemann-Pick C disease, it's specific for lipids such as cholesterol or sphingolipids inside the cell that need to be recycled."

"The early onset of the late infantile onset usually occurs before the age of 10. Then, you have the juvenile and adult-onset, which usually occurs after the age of 10 and have different types of symptoms. Once you have the neurological symptoms, they usually start with delay in motor milestones in the younger children. But most often, we see a diagnosis happening between the ages of, say, three and seven, starting with problems in walking, stability or gait problems, clumsiness, delay in speech, or losing the ability to speak appropriately, as well as seizures, problems at school, problems to follow direction at school, some behavioral problems."

#ZevraTherapeutics #RareDisease #OrphanDisease #NiemannPick #NPC #NiemannPickAwareness #PediatricRareDisease

zevra.com

Download the transcript here

  continue reading

2103 에피소드

All episodes

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드

탐색하는 동안 이 프로그램을 들어보세요.
재생